Novel parenteral carbamazepine formulation
AssigneeLundbeck Pharmaceuticals LLC
InventorsJames CLOYD, Angela BIRNBAUM, Ilo LEPPIK, Stephen D. COLLINS
Life of this patent
Estimating the term…
Loading patent…
AssigneeLundbeck Pharmaceuticals LLC
InventorsJames CLOYD, Angela BIRNBAUM, Ilo LEPPIK, Stephen D. COLLINS
Estimating the term…
The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.
A method of treating partial seizures with complex symptoms, generalized tonic-clonic seizures, or mixed seizure patterns in a comprising,
The method of claim 5, wherein administration of each infusion occurs over a period of about 5 minutes.
A method of treating epilepsy or status epilipticus in a subject comprising,
A method of treating partial seizures with complex symptoms, generalized tonic-clonic seizures, or mixed seizure patterns in a subject comprising, a) providing a composition comprising about 10 mg/mL carbamazepine and about 25% w/v of a modified cyclodextrin, for example a sulfobutylether-7-(3-cyclodextrin;
Dependencies are inferred from the claim text.